August 02, 2012
Article
An overview of the utilization and cost for selected oral antineoplastic agents, with discussion regarding oncology in general, as well as the topic of adherence.
May 31, 2012
New and forthcoming oral anticoagulants, which do not require prothrombin time monitoring, will offer patients and providers additional therapeutic options.
April 05, 2012
Incivek and Victrelis, approved for Hepatitis C within weeks of each other in May 2011, look to change the way the disease is treated.
December 09, 2011
Uptake of the new oral agents gilenya and Ampyra may be expected to increase rapidly in the future, if for largely different reasons.
October 06, 2011
Approvals of potential blockbuster drugs represent a new source of revenue for pharmaceutical manufacturers, who will experience significant income loss from generic competition in 2011-2012.
August 08, 2011
Significant factors for 2011 prescription utilization include the recession, change in employment rate, new generic and brand launches, and changes in Baby Boomers' retirement plans.